623 related articles for article (PubMed ID: 16778319)
1. Current scenario of drug development for leishmaniasis.
Croft SL; Seifert K; Yardley V
Indian J Med Res; 2006 Mar; 123(3):399-410. PubMed ID: 16778319
[TBL] [Abstract][Full Text] [Related]
2. Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives.
Croft SL; Engel J
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S4-8. PubMed ID: 16904717
[TBL] [Abstract][Full Text] [Related]
3. Drug combinations for visceral leishmaniasis.
Olliaro PL
Curr Opin Infect Dis; 2010 Dec; 23(6):595-602. PubMed ID: 20871400
[TBL] [Abstract][Full Text] [Related]
4. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
[TBL] [Abstract][Full Text] [Related]
5. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
[TBL] [Abstract][Full Text] [Related]
6. Susceptibility of clinical isolates of Leishmania aethiopica to miltefosine, paromomycin, amphotericin B and sodium stibogluconate using amastigote-macrophage in vitro model.
Utaile M; Kassahun A; Abebe T; Hailu A
Exp Parasitol; 2013 May; 134(1):68-75. PubMed ID: 23434530
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.
Seifert K; Croft SL
Antimicrob Agents Chemother; 2006 Jan; 50(1):73-9. PubMed ID: 16377670
[TBL] [Abstract][Full Text] [Related]
8. Leishmaniasis: an update of current pharmacotherapy.
Sundar S; Chakravarty J
Expert Opin Pharmacother; 2013 Jan; 14(1):53-63. PubMed ID: 23256501
[TBL] [Abstract][Full Text] [Related]
9. In vitro drug susceptibility of Leishmania infantum isolated from humans and dogs.
Maia C; Nunes M; Marques M; Henriques S; Rolão N; Campino L
Exp Parasitol; 2013 Sep; 135(1):36-41. PubMed ID: 23747751
[TBL] [Abstract][Full Text] [Related]
10. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
Bhandari V; Kulshrestha A; Deep DK; Stark O; Prajapati VK; Ramesh V; Sundar S; Schonian G; Dujardin JC; Salotra P
PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478
[TBL] [Abstract][Full Text] [Related]
11. Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs.
Hadighi R; Boucher P; Khamesipour A; Meamar AR; Roy G; Ouellette M; Mohebali M
Parasitol Res; 2007 Oct; 101(5):1319-22. PubMed ID: 17610079
[TBL] [Abstract][Full Text] [Related]
12. Current diagnosis and treatment of visceral leishmaniasis.
Mondal S; Bhattacharya P; Ali N
Expert Rev Anti Infect Ther; 2010 Aug; 8(8):919-44. PubMed ID: 20695748
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
Rahman R; Goyal V; Haque R; Jamil K; Faiz A; Samad R; Ellis S; Balasegaram M; Boer MD; Rijal S; Strub-Wourgaft N; Alves F; Alvar J; Sharma B
PLoS Negl Trop Dis; 2017 May; 11(5):e0005635. PubMed ID: 28558062
[TBL] [Abstract][Full Text] [Related]
14. Comparison of
Özbilgin A; Çavuş İ; Kaya T; Yıldırım A; Harman M
Turkiye Parazitol Derg; 2020 Mar; 44(1):12-16. PubMed ID: 32212583
[TBL] [Abstract][Full Text] [Related]
15. Leishmaniasis chemotherapy--challenges and opportunities.
Croft SL; Olliaro P
Clin Microbiol Infect; 2011 Oct; 17(10):1478-83. PubMed ID: 21933306
[TBL] [Abstract][Full Text] [Related]
16. Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis.
Parvez S; Yadagiri G; Gedda MR; Singh A; Singh OP; Verma A; Sundar S; Mudavath SL
Sci Rep; 2020 Jul; 10(1):12243. PubMed ID: 32699361
[TBL] [Abstract][Full Text] [Related]
17. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
[TBL] [Abstract][Full Text] [Related]
18. Recurrence of visceral and muco-cutaneous leishmaniasis in a patient under immunosuppressive therapy.
Darcis G; Van der Auwera G; Giot JB; Hayette MP; Tassin F; Arrese Estrada J; Cnops L; Moutschen M; de Leval L; Leonard P
BMC Infect Dis; 2017 Jul; 17(1):478. PubMed ID: 28687071
[TBL] [Abstract][Full Text] [Related]
19. [Canine leishmaniasis: evolution of the chemotherapeutic protocols].
Oliva G; Foglia Manzillo V; Pagano A
Parassitologia; 2004 Jun; 46(1-2):231-4. PubMed ID: 15305724
[TBL] [Abstract][Full Text] [Related]
20. Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator-Picroliv.
Shakya N; Sane SA; Vishwakarma P; Bajpai P; Gupta S
Acta Trop; 2011 Aug; 119(2-3):188-93. PubMed ID: 21679679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]